19th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160129067 | USE OF INSTANT ASPARAGUS POWDER IN FOOD, MEDICINE AND HEALTH FOOD - Disclosed is use of an asparagus powder in medicines, food, and health foods for treatment of anxiety and depressive mental disorders, with active ingredients in the asparagus powder including: 15.0% or more of an asparagus saponin, 8% or more of a polysaccharide, 3.0% or more of a polyphenol, and 2.0% or more of a flavone. | 2016-05-12 |
20160129068 | COMPOSITION OF PLANT EXTRACT AND ITS PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - The present invention is related to a composition for relieving joint inflammation. The present invention is also related to a method for treatment of joint inflammation, comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition. By means of inhibiting the COX-2 and NF-κB expression through the composition or the pharmaceutical composition with specific ratio, the joint inflammation and swelling could be reduced and the osteoclasts proliferation could be decreased to mitigate bone erosion, osteoporosis and degenerative arthritis. | 2016-05-12 |
20160129069 | METHOD FOR INDUCING PROLIFERATION OF DOPAMINERGIC CELLS - A method for inducing a proliferation of dopaminergic cells in a subject in need, comprising: administering a herbal medicinal composition to a subject in need, wherein the herbal medicinal composition comprises: | 2016-05-12 |
20160129070 | Glutathione Disulfide Compositions and Related Methods for the Treatment of Cancer - Compositions and methods for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a GSSG and a carrier thereof. In an aspect, the carrier is a liposome. In a further aspect, the liposome is a positively charged liposome. | 2016-05-12 |
20160129071 | NUTRITIONAL SUPPLEMENTS CONTAINING A PEPTIDE COMPONENT AND USES THEREOF - The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and | 2016-05-12 |
20160129072 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION - The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less. | 2016-05-12 |
20160129073 | Method for Inhibiting HIV Replication in Mammal and Human Cells - The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton. | 2016-05-12 |
20160129074 | SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are methods of formulating cyclosporin A Form 2. | 2016-05-12 |
20160129075 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE - Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. | 2016-05-12 |
20160129076 | EXTRACELLULAR MATRIX-BINDING SYNTHETIC PEPTIDOGLYCANS - This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use. | 2016-05-12 |
20160129077 | Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma - A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma. | 2016-05-12 |
20160129078 | Rhomboid Proteins and Uses Thereof - Compositions and methods for managing the growth, life cycle, functionality, or biological progression of cells, tissues, and organisms by introducing rhomboid proteins or peptides into the internal and external environment of the cells, tissues, and organisms. In particular, embodiments comprise compositions and methods for overcoming drug resistance in disease, and for sensitizing cells, tissues, and organisms to agents to treat disease, and methods for producing such compositions. The compositions and methods include rhomboid proteins, polypeptides, and/or peptides, and nucleic acids encoding such proteins, polypeptides, and/or and peptides, corresponding to the | 2016-05-12 |
20160129079 | SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS - The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof. | 2016-05-12 |
20160129080 | TREATMENT OF POLYPOIDAL CHROIDAL VASCULOPATHY - Patients with polypoidal choroidal vasculopathy receive a combination of both (i) a photodynamic therapy, such as verteporfin and (ii) a non-antibody VEGF antagonist. | 2016-05-12 |
20160129081 | Oral Treatment Of Inflammatory Bowel Disease - Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described. | 2016-05-12 |
20160129082 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 2016-05-12 |
20160129083 | MIC-1 FUSION PROTEINS AND USES THEREOF - The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds. | 2016-05-12 |
20160129084 | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure - The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 2016-05-12 |
20160129085 | COMPOSITIONS AND METHODS FOR INHIBITING THE BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES - The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful. | 2016-05-12 |
20160129086 | INTERFERON LAMBDA-ANTIBODY COMPLEXES - The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-λ alone, antibody alone, or the combination of unconjugated interferon-λ and antibody. | 2016-05-12 |
20160129087 | RAPID-ACTING INSULIN COMPOSITIONS - The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products. | 2016-05-12 |
20160129088 | PRESERVATIVE FREE INSULIN FORMULATIONS AND SYSTEMS AND METHODS FOR AEROSOLIZING - One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation. | 2016-05-12 |
20160129089 | COMBINATION THERAPY - The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a Somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need. | 2016-05-12 |
20160129090 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 2016-05-12 |
20160129091 | TOPICAL THERAPEUTIC FORMULATIONS - The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites. | 2016-05-12 |
20160129092 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 2016-05-12 |
20160129093 | COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN OR DERIVATIVES THEREOF - Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure. | 2016-05-12 |
20160129094 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF - The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1. | 2016-05-12 |
20160129095 | Immunostimulatory Combinations - The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. | 2016-05-12 |
20160129096 | GASTRIN PEPTIDE IMMUNOGENIC COMPOSITION - The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases. | 2016-05-12 |
20160129097 | METHOD OF PROCESSING A VETERINARY TUMOR VACCINE AND A VETERINARY TUMOR VACCINE PROCESSING KIT - The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells. Cells can then be mixed with an unmethylated single stranded oligodeoxynucleotide chain adjuvant to formulate a vaccine and then administered to a subject. The vaccines can be autologous, allogeneic or hybrids thereof to the subject. | 2016-05-12 |
20160129098 | TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS - It is disclosed herein that B cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid DNA. Based on this finding, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines are co-administered with a B cell targeting agent, B-cell recruiting agent, or a monocyte or dendritic cell recruiting agent. To increase the immunogenicity of the DNA vaccines, the B cell targeting agent or B cell recruiting agent is administered at the same location where the DNA vaccine is administered. In contrast, the monocyte or dendritic cell recruiting agent can be administered in a different location, in order to recruit cells competing with the B cells for DNA uptake away from the location where the DNA vaccine is administered. | 2016-05-12 |
20160129099 | TREATMENT AND PREVENTION OF MALARIA - There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof. | 2016-05-12 |
20160129100 | IMMUNGENIC TP0751 FRAGMENTS - The present application provides methods of stimulating an immune response, such as a protective immune response against | 2016-05-12 |
20160129101 | IMMUNOGENIC COMPOSITION FOR USE IN THERAPY - This application relates to immunogenic compositions comprising a | 2016-05-12 |
20160129102 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS - Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4. | 2016-05-12 |
20160129103 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 2016-05-12 |
20160129104 | HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF - The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. | 2016-05-12 |
20160129105 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-12 |
20160129106 | Method for preparing virosomes - This disclosure relates to methods for preparing a virosome preparation comprising viral envelope protein of at least two, preferably at least three, more preferably at least four, different enveloped viruses, as well as to virosomal preparations obtained thereby. The disclosure also relates to the use of the virosomal preparations, e.g., as a vaccine. | 2016-05-12 |
20160129107 | MUTATED NON-PRIMATE LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS - A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. | 2016-05-12 |
20160129108 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF - The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression. | 2016-05-12 |
20160129109 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 2016-05-12 |
20160129110 | IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS - Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab) | 2016-05-12 |
20160129111 | METHODS FOR DELIVERING AN ANTI-CANCER AGENT TO A TUMOR - Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves
| 2016-05-12 |
20160129112 | Pharmaceutical Compositions Comprising Pyrophosphate - Described herein are therapeutic compositions comprising a therapeutic agent and pyrophosphate. | 2016-05-12 |
20160129113 | TABLETS COMPRISING A TASTE MASKING AGENT - The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds. | 2016-05-12 |
20160129114 | LIQUID COMPOSITION, PROCESS FOR PRODUCING THE LIQUID COMPOSITION, AND ECTOPARASITE CONTROLLING AGENT FOR USE IN MAMMALS AND AVIANS - A liquid composition comprising (a) 21 to 70 parts by weight of a solvent having no nitrogen atom and having a carbonyl or sulfonyl group in the molecule, (b) 30 to 78.9 parts by weight of at least one component selected from the group consisting of a non-cyclic alcohol, an alkylene glycol, a polyalkylene glycol, a triol, a glycol monoacetate and a glycol monoalkyl ether, (c) 0.001 to 30 parts by weight of a physiologically active ingredient, and (d) 0.001 to 49 parts by weight of water. | 2016-05-12 |
20160129115 | FORMULATIONS OF LIQUID STABLE ANTITHROMBIN - In one aspect, the invention provides liquid stable formulations of antithrombin. | 2016-05-12 |
20160129116 | Transdermal Drug Delivery using an Osmolyte and Vasoactive Agent - A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient. | 2016-05-12 |
20160129117 | Novel Boronic Acid Compound Preparation - The purpose of the present invention is to avoid side effects from contained medicines. Provided are: a preparation obtained by mixing a boronic acid compound and a block copolymer represented by general formula (I); and a production method therefor. | 2016-05-12 |
20160129118 | COHESIVE LIQUID BOLUS COMPRISING BIOACTIVES - This invention relates to a cohesive thin liquid bolus comprising an aqueous solution of at least one food grade biopolymer and at least one bioactive compound, to the use of said cohesive thin liquid bolus for promoting safer swallowing of food boluses in dysphagic patients and to a method for preparing the bolus. | 2016-05-12 |
20160129119 | DISPERSION AND METHOD FOR FORMING HYDROGEL - An object is to provide dispersion containing lipid peptide type compound useful as low molecular weight gelator, such as lipid dipeptide and lipid tripeptide, and dissolution accelerator capable of dissolving the lipid peptide type compound at lower temperature and more easily. It is also an object to provide dispersion that can form hydrogel by simpler method and under milder condition (low temperature) and from which gel can be obtained as gel having high thermal stability, and provide method for forming the gel. Dispersion including: a lipid peptide type compound in which peptide portion formed by repetition of at least two or more identical or different amino acids is bonded to lipid portion including C | 2016-05-12 |
20160129120 | NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS - A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof. | 2016-05-12 |
20160129121 | FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 2016-05-12 |
20160129122 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES - The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate. | 2016-05-12 |
20160129123 | Derivatisation of Erythropoietin (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2016-05-12 |
20160129124 | Derivatisation of Erythropoietin (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2016-05-12 |
20160129125 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES - A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders. | 2016-05-12 |
20160129126 | CHEMICAL CROSSLINKERS - Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate. | 2016-05-12 |
20160129127 | Development of Soluble Albuminated Curcumin for Application in Cancer Therapy - This invention relates to an albumin-curcumin conjugate for application in cancer therapy, including albumin and curcumin. | 2016-05-12 |
20160129128 | ANTIBODY DRUG CONJUGATES - Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R | 2016-05-12 |
20160129129 | IGG4 FC FRAGMENT COMPRISING MODIFIED HINGE REGION - The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate. | 2016-05-12 |
20160129130 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES - Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5. | 2016-05-12 |
20160129131 | Shielded Targeting Agents, Methods, and In Vivo Diagnostic System - A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided. | 2016-05-12 |
20160129132 | Process for Preparing Stealth Nanoparticles - A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine. | 2016-05-12 |
20160129133 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule. | 2016-05-12 |
20160129134 | COMPOSITIONS COMPRISING CROSS-LINKED HYALURONIC ACID AND CYCLODEXTRIN - The present invention relates to a hyaluronic acid composition comprising a hyaluronic acid and one or more cyclodextrin molecules covalently bound to said hyaluronic acid via a bi- or polyfunctional crosslinking agent, wherein the covalent bonds between said hyaluronic acid and said crosslinking agent and between said crosslinking agent and said cyclodextrin molecules are ether bonds. The present invention relates to medical and cosmetic (non-medical) uses of such compositions further comprising a pharmaceutical or medical agent and to a method of preparing a slow release formulation. | 2016-05-12 |
20160129135 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 | 2016-05-12 |
20160129136 | NOVEL COMPOSITIONS AND USES THEREOF - Compositions comprising one or more nanoparticles, wherein the nanoparticles encapsulate fluorescence dyes are disclosed. In one embodiment, the nanoparticle comprises triterpene. In another embodiment, the nanoparticle comprises triterpene and fatty ester. Methods for performing a diagnostic or a therapeutic procedure comprising administering to a subject an effective amount of the compositions of the present invention or carbocyanine dyes are also provided. | 2016-05-12 |
20160129137 | COMPOSITION FOR MONITORING AGED TISSUES, COMPRISING BACTERIA, AND USE THEREOF - A recombinant bacterium for detecting aged tissues and a method of detecting aged tissues in a subject, and a composition for delivering a drug to aged tissues are provided. | 2016-05-12 |
20160129138 | OCTAPOD IRON OXIDE NANOPARTICLES AS HIGH PERFORMANCE T2 CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING - Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles. | 2016-05-12 |
20160129139 | Method for Purification of 18F-Labeled Choline Analogues - The present invention relates to a method for purification of 18F-labeled choline analogues in a solution injectable to a patient, prepared using non-gaseous synthesis paths, comprising a step of solid phase extraction (SPE) purification using a solid support, wherein the solid support used in the solid phase extraction purification has the characteristic to retain impurities and reagents from the solution but not the 18F-labeled choline analogues. | 2016-05-12 |
20160129140 | Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy - Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice. | 2016-05-12 |
20160129141 | DECONTAMINATION DEVICE FOR MEDICAL MATERIAL - A decontamination device for medical material, including a support intended to receive and hold said medical material to be decontaminated on a predefined axis, a spraying means, a drying means and an irradiating means, wherein said spraying means is mounted in rotation about said predefined axis and in translation parallel to said predefined axis, in such a way that the spraying is directed towards said predefined axis, said drying means is mounted in translation parallel to said predefined axis, and said irradiating means is mounted in translation parallel to said predefined axis. | 2016-05-12 |
20160129142 | SYSTEM AND METHOD FOR REDUCING GERMS BY MEANS OF PLASMA - Disclosed is a system for reducing germs by means of plasma. To this end, a piezoelectric transformer is associated with a dielectric film. The peripheral edge of the dielectric film encloses an area to be sterilized, a cavity being formed thereby. A high-voltage end of the piezoelectric transformer is facing a side of the dielectric film facing away from the cavity. The plasma is ignited within the cavity. | 2016-05-12 |
20160129143 | Odor Elimination System - A odor elimination system includes a pad that may be positioned on a support surface and a carpet is positioned on the pad. An injection unit is provided and the injection unit contains a fluid odor eliminator. The injection unit includes a plurality of needles. The needles penetrate the carpet and the pad. Thus, the injection unit may deliver the fluid odor eliminator into the pad thereby facilitating the fluid odor eliminator to eliminate an odor associated with a contaminant in the carpet and the pad. | 2016-05-12 |
20160129144 | MALODOR CONTROL COMPOSITION HAVING A MIXTURE OF VOLATILE ALDEHYDES AND METHODS THEREOF - A malodor control composition having a mixture of volatile aldehydes and methods thereof are provided. The composition is suitable for a variety of applications, including use in fabric and air freshening products. | 2016-05-12 |
20160129145 | METHOD OF NEUTRALIZING MALODORS - A method of neutralizing malodors by providing a malodor control composition having a mixture of volatile aldehydes is provided. In some embodiments, the malodor control composition includes an acid catalyst. | 2016-05-12 |
20160129146 | Device for Diffusing Volatile Substances - The device for diffusing volatile substances, comprising a casing ( | 2016-05-12 |
20160129147 | SPILL-RESISTANT AIR FRESHENER CANISTER - The present invention provides a spill-resistant air freshener canister that includes: a supply vessel filled with aromatic liquid that has a threaded mouth sealed with a puncturable foil/polyethylene membrane; a cylindrical inner sleeve incorporating a socket that sealably engages the threaded mouth of the supply vessel, the sleeve also having a cylindrical axial aperture at the bottom of the socket, and at least one seepage aperture at the very bottom of the socket which enables liquid from inside the supply vessel to escape in a radially outward direction to the exterior of the inner cylindrical sleeve; a cylindrical wick surrounding the cylindrical inner sleeve; and an evaporator cage into which the cylindrical inner sleeve is inserted, the evaporator cage having a fully-enclosed bottom portion containing a central projecting blade that fits through the axial aperture at the bottom of the socket. The bottom portion is ultrasonically welded to the bottom of the cylindrical inner sleeve. | 2016-05-12 |
20160129148 | Nano-calcium phosphate-coated polymethylmethacrylate-based co-polymer and coating process of the same - The present invention relates to a method for coating polymethylmethacrylate (PMMA)-based co-polymer beads with nano-calcium phosphate. The method includes synthesizing the PMMA-based co-polymer beads containing hydroxyl pendant group, reacting the calcium salt and phosphate solution with the hydroxyl pendant group on the PMMA-based co-polymer beads, and thickening of the nano-calcium phosphate coating on the PMMA-based co-polymer beads. | 2016-05-12 |
20160129149 | IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL - Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings. | 2016-05-12 |
20160129150 | SUGAR CHAIN-POLYPEPTIDE COMPLEX - The object of the present invention is to provide a sugar chain-polypeptide complex that may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a sugar chain-polypeptide complex, characterized in that said polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide. | 2016-05-12 |
20160129151 | PROTEIN BASED MATERIALS - Gels and films can be formed from protein dissolved into a benign solvent that comprises alcohol, water, and salt. In one example, the protein can be collagen. In one example, the benign solvent can include a water to alcohol ratio of between ninety-nine-to-one and one-to-ninety-nine by volume, a salt concentration between zero moles per liter and the maximum salt concentration soluble in water, and a protein amount of between near zero percent and about 25 percent by weight as compared to the mixture of water and alcohol. Once the protein is dissolved in the benign solvent, secondary processing steps can be conducted to form protein based bioadhesives, gels, and films with desirable physical properties. Additional process steps can include washings that improve the properties of the protein structures. | 2016-05-12 |
20160129152 | CONSISTENT CALCIUM CONTENT BONE ALLOGRAFT SYSTEMS AND METHODS - Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor. | 2016-05-12 |
20160129153 | METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL - The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels. | 2016-05-12 |
20160129154 | AMNIOTIC MEMBRANE - The invention relates to a preserved amniotic membrane, in particular a vacuum-dried amniotic membrane. It also relates to uses of vacuum-dried amniotic membrane and methods for making a vacuum-dried amniotic membrane. A method of processing an amniotic membrane to provide a vacuum-dried amniotic membrane,comprising the step of vacuum-drying the amniotic membrane Amniotic membrane (AM) is the inner most extraembryonic membrane that surrounds the foetus in a sac of amniotic fluid, functioning as a protective barrier to ascending infection and trauma during pregnancy. | 2016-05-12 |
20160129155 | MUSCULOSKELETAL TISSUE FABRICATION - Described herein are methods of fabricating human cell-based engineered musculoskeletal tissues (hCEMTs) using three dimensional fabrication technology that involves injectable materials with in situ polymerization/solidification capability and/or solid free-form fabrication. Also described is the usage of hCEMTs for tissue repair and drug testing. | 2016-05-12 |
20160129156 | Method of a Pharmaceutical Delivery System for Use Within a Joint Replacement - Methods and apparatus of providing a joint replacement parts with a pharmaceutical delivery system is provided. The pharmaceutical delivery system is placed within the joint replacement parts to provide, over a period of time, sustained release of a controlled concentration of pharmaceuticals within the joint space of the joint replacement and to produce a local or systemic physiological of pharmacological effect. | 2016-05-12 |
20160129157 | Implantable Devices for Bone or Joint Defects - In one aspect, the invention provides an implantable device comprising a uniform mixture of components including degradable polymer, inorganic bone particulate either natural or synthetic, a drug, and a soluble microporagen. In some embodiments, the uniform mixture further includes a soluble polymer macroporagen. In some embodiments, the uniform mixture is coated with an immobilized outer porous layer comprising or consisting of synthetic or natural inorganic bone granules. In further aspects, the invention provides an implantable device comprising a composite core of degradable polymer, bone, and a drug, and a coating comprising or consisting of microporous bone overlayer covering the degradable composite core. | 2016-05-12 |
20160129158 | Multilayer Medical Balloon - An expandable medical balloon including an inner layer formed of a poly (ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same. | 2016-05-12 |
20160129159 | MEDICAL DEVICES HAVING ENHANCED PERFORMANCE - In some aspects, the present disclosure provides medical devices that comprise a composite region comprising a binding polymer portion and an oriented fibrous polymer reinforcement portion, wherein the composite region is formed by a process that comprises heating and compressing one or more oriented polymer fibers. Other aspects of the present disclosure relative to methods of forming such medical devices. | 2016-05-12 |
20160129160 | SKIVED FILM FOR COVERING SURFACE OF PLUG FOR MEDICAL PURPOSES, PLUG FOR MEDICAL PURPOSES USING SAID FILM, PRE-FILLED SYRINGE USING SAID PLUG, AND METHOD FOR PRODUCING SAID FILM - A method to make a PTFE skived film capable of exhibiting, with a single layer, sliding properties, barrier properties with regard to a liquid contact surface, and excellent tear resistance during injection molding. This skived film is obtained by cutting a polytetrafluoroethylene block or a modified polytetrafluoroethylene block subjected to a thermal fusion treatment under reduced pressure or subjected to a pressurized thermal fusion treatment after being subjected to fusion under reduced pressure. | 2016-05-12 |
20160129161 | COMPOSITIONS AND DEVICES INCORPORATING WATER-INSOLUBLE THERAPEUTIC AGENTS AND METHODS OF THE USE THEREOF - Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices | 2016-05-12 |
20160129162 | Protected Magnesium Alloys for Bioresorbable Stents - Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy. | 2016-05-12 |
20160129163 | OSTEOBLAST STIMULATING ORTHOPEDIC IMPLANT - Nanomaterials for neural and orthopedic prostheses are disclosed. Composite carbon nanofibers enhance neuronal growth and minimize glial scar tissue formation. Methods and compositions to promote neuronal growth and minimize scar tissue formation during prolonged monitoring and treatment of neural tissue are disclosed. Composite polyurethane carbon nanofiber is a suitable material for neural implant. Composite carbon nanomaterials decrease adhesion of astrocytes and fibroblasts. | 2016-05-12 |
20160129164 | MICRO-NEEDLE AND MICRO-NEEDLE PATCH - Provided are micro-needles and a micro-needle patch for transdermal delivery of a pharmaceutical, medical, or cosmetic substance. The micro-needle may include a biocompatible matrix having a micro-needle-like shape; and porous particles provided at at least a portion of a surface or the interior of the biocompatible matrix. | 2016-05-12 |
20160129165 | MEDICAL DEVICES HAVING BIOERODABLE LAYERS FOR THE RELEASE OF THERAPEUTIC AGENTS - According to an aspect of the present invention, medical devices are provided which comprise: (a) a substrate and (b) bioerodable polymeric layer over the substrate that contains (i) one or more biodegradable polymers (ii) one or more therapeutic agents, and (iii) one or more plasticizers. | 2016-05-12 |
20160129166 | IMPLANTABLE MATERIAL GRAFTED WITH A CELL ANTIPROLIFERATIVE AND/OR ANTIBACTERIAL FILM SYNTHETIZED FROM A BIFUNCTIONAL MOLECULE - The present invention relates to an implantable material having at least one external surface grafted with a film including carboxylate and sulfonate functions wherein the film is simultaneously synthesized and grafted directly on the external surface by radical reaction of a bifunctional adhesion primer of Formula (I) or by radical reaction of an adhesion primer and a bifunctional polymerizable monomer of Formula (II). | 2016-05-12 |